Quality of life in oncology and quality of life in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma
Journal Title: OncoReview - Year 2011, Vol 1, Issue 4
Abstract
Introduction of molecularly targeted agents into clinical practice has led to marked progress in pharmacotherapy of advanced renal cell carcinoma. There have been six drugs of the therapeutic class registered to date. Further registration is expected next year. Targeted therapy proved to prolong time to disease progression of renal cell cancer. If administered sequentially they prolong overall survival as well. The treatment usually tends to last. The disease gains status of chronic illness. Molecular predictive factors are not available and decisions regarding specific therapeutic choices are based on clinical factors. Due to all aforementioned the toxicity profile and related quality of life should be of special interest. The article is the discussion of methodology of quality of life clinical trials, the data collection, data analysis and review of current knowledge regarding this issue in context of treatment of renal cell carcinoma based on molecularly targeted therapy.
Authors and Affiliations
Jakub Żołnierek, Piotr Wysocki
Keywords
Related Articles
- EP ID EP53129
- DOI -
- Views 226
- Downloads 0
Octreotide LAR in neuroendocrine tumors - a summary of the experience
Neuroendocrine tumors are a rare and heterogeneous group of neoplasms. Most of the patient is diagnosed with locally advanced or metastatic disease and curative surgery is rarely an option. Somatostatin analogues have b...
Idiopathic venous thromboembolism or occult cancer?
The relationship between cancer and an increased incidence of venous thromboembolism (VTE) is well documented. VTE is a common complication of cancer, which usually occurs in the advanced stages of the disease. It often...
Badanie kliniczne III fazy oceniające zastosowanie pazopanibu w leczeniu raka nerki – komentarz do badania
Nowe możliwości celowanego leczenia uogólnionego raka piersi z ekspresją receptorów hormonalnych
Badania molekularne wykazały, że rak piersi jest grupą heterogennych chorób o różnych cechach biologicznych i różnym rokowaniu. Z klinicznego punktu widzenia raka piersi podzielić można na trzy różne typy o odmiennej pod...
Dermatofibrosarcoma protuberans (DFSP) – postępy w diagnostyce i leczeniu
Dermatofibrosarcoma protuberans jest rzadkim, rosnącym powierzchownie, mięsakiem tkanek miękkich występującym z częstością ok. 4 przypadków na milion osób rocznie. Zwykle rozwija się na skórze tułowia, występuje we wszys...